Literature DB >> 7200956

Immune response of neonates to pneumococcal polysaccharide-protein conjugate.

K T Lin, C J Lee.   

Abstract

Immune responses were studied in adult and young mice exposed to pneumococcal 6A and 19F polysaccharides (PSs), as well as 19F PS conjugated to proteins, e.g. human immunoglobulin G (HIgG), pneumococcal R61 cell wall polypeptide, and bovine serum albumin (BSA). Significantly higher IgM and IgG2 antibody titres were induced in mice receiving 19F PS-protein conjugates than in the control group receiving 19F PS alone. Maternal immunization with 19F PS-HIgG conjugate elicited a low immune response in the offspring. However, when young mice from immunized mothers were given and additional dose of polysaccharide-protein conjugate, they gave an antibody response greater than that of mice not given additional immunogen. Similarly, young mice exposed to 14-valent pneumococcal vaccine during gestation produced higher antibody response to 6A and 19F PSs. Secondary immunization of 19F PS or PS-protein conjugate at 1 or 2 weeks after primary immunization did not enhance antibody formation but rather suppressed the immune response to that polysaccharide.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7200956      PMCID: PMC1555384     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  37 in total

1.  GM GENES AND GAMMA-G-GLOBULIN SYNTHESIS IN THE HUMAN FETUS.

Authors:  H H FUDENBERG
Journal:  J Immunol       Date:  1965-04       Impact factor: 5.422

2.  The bacteriology of pneumococcal otitis media.

Authors:  R Austrian; V M Howie; J H Ploussard
Journal:  Johns Hopkins Med J       Date:  1977-09

3.  Regulation of the antibody response to type III pneumococcal polysaccharide. V. Ontogeny of factors influencing the magnitude of the plaque-forming cell response.

Authors:  H C Morse; B Prescott; S S Cross; P W Stashak; P J Baker
Journal:  J Immunol       Date:  1976-02       Impact factor: 5.422

Review 4.  Developmental aspects of immunity.

Authors:  J Sterzl; A M Silverstein
Journal:  Adv Immunol       Date:  1967       Impact factor: 3.543

5.  Effect of maternal immunization on the antibody response of low responder rats.

Authors:  T J Gill; H W Kunz; B K Davis
Journal:  Int Arch Allergy Appl Immunol       Date:  1977

6.  Immunochemical properties of oligosaccharide-protein conjugates with Klebsiella-K2 specificity. I. Specificity and crossreactivity of anti-conjugate versus anti-bacterial antibodies.

Authors:  H Geyer; S Stirm; K Himmelspach
Journal:  Med Microbiol Immunol       Date:  1979-01-24       Impact factor: 3.402

7.  Prevention of pneumococcal infection by immunization with capsular polysaccharides of Streptococcus pneumoniae: current status of polyvalent vaccines.

Authors:  R Austrian
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

8.  ANTIBODY TO HEREDITARY HUMAN GAMMA-GLOBULIN (GM) FACTOR RESULTING FROM MATERNAL-FETAL INCOMPATIBILITY.

Authors:  H H FUDENBERG; B R FUDENBERG
Journal:  Science       Date:  1964-07-10       Impact factor: 47.728

9.  Comparative immunogenicity of group 6 pneumococcal type 6A(6) and type 6B(26) capsular polysaccharides.

Authors:  J B Robbins; C J Lee; S C Rastogi; G Schiffman; J Henrichsen
Journal:  Infect Immun       Date:  1979-12       Impact factor: 3.441

10.  CHEMO-IMMUNOLOGICAL STUDIES ON CONJUGATED CARBOHYDRATE-PROTEINS : XII. THE IMMUNOLOGICAL PROPERTIES OF AN ARTIFICIAL ANTIGEN CONTAINING CELLOBIURONIC ACID.

Authors:  W F Goebel
Journal:  J Exp Med       Date:  1938-09-30       Impact factor: 14.307

View more
  11 in total

Review 1.  Immunogenicity and immunochemistry of Streptococcus pneumoniae capsular polysaccharides.

Authors:  J E van Dam; A Fleer; H Snippe
Journal:  Antonie Van Leeuwenhoek       Date:  1990-06       Impact factor: 2.271

2.  Purification and immunogenicity of genetically obtained pneumolysin toxoids and their conjugation to Streptococcus pneumoniae type 19F polysaccharide.

Authors:  J C Paton; R A Lock; C J Lee; J P Li; A M Berry; T J Mitchell; P W Andrew; D Hansman; G J Boulnois
Journal:  Infect Immun       Date:  1991-07       Impact factor: 3.441

3.  The pneumococcus: host-organism interactions and their implications for immunotherapy and immunoprophylaxis.

Authors:  F E Perry; J R Catterall
Journal:  Thorax       Date:  1994-10       Impact factor: 9.139

4.  Antibody responses of splenectomized patients with non-Hodgkin's lymphoma to immunization with polyvalent pneumococcal vaccines.

Authors:  S Petrasch; O Kühnemund; A Reinacher; M Uppenkamp; R Reinert; W Schmiegel; R Lütticken; G Brittinger
Journal:  Clin Diagn Lab Immunol       Date:  1997-11

Review 5.  Pneumococcal resistance to antibiotics.

Authors:  K P Klugman
Journal:  Clin Microbiol Rev       Date:  1990-04       Impact factor: 26.132

6.  Maternal immunity and antibody response of neonatal mice to pneumococcal type 19F polysaccharide.

Authors:  C J Lee; E D Ching; J H Vickers
Journal:  J Clin Microbiol       Date:  1991-09       Impact factor: 5.948

7.  Antibody responses to Haemophilus influenzae type b and diphtheria toxin induced by conjugates of oligosaccharides of the type b capsule with the nontoxic protein CRM197.

Authors:  P Anderson
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

8.  Modulation of the immune response to pneumococcal type 14 capsular polysaccharide-protein conjugates by the adjuvant Quil A depends on the properties of the conjugates.

Authors:  A F Verheul; A A Versteeg; M J De Reuver; M Jansze; H Snippe
Journal:  Infect Immun       Date:  1989-04       Impact factor: 3.441

9.  Immunogens consisting of oligosaccharides from the capsule of Haemophilus influenzae type b coupled to diphtheria toxoid or the toxin protein CRM197.

Authors:  P Anderson; M E Pichichero; R A Insel
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

10.  Characterization of the murine immune response to type 6 pneumococcal polysaccharide.

Authors:  R L Fairchild; H Braley-Mullen
Journal:  Infect Immun       Date:  1983-02       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.